In a 12 month open study of itraconazole in pulmonary aspergilloma nine patients received oral itraconazole 200 mg daily for six months followed by further itraconazole or observation for a further six months. There was no change in the serum IgG specific for Aspergillus fumigatus (mean (SE) change -4% (10%)) or symptoms of chronic cough and haemoptysis. In two of the three patients who continued treatment beyond six months symptoms and radiographic appearances improved and a temporary reduction in A fumigatus specific IgG occurred in one patient. Further experience of the effects of longer treatment are needed before oral itraconazole can be recommended for aspergilloma.
Pulmonary aspergillomas are a recognised complication of cavitating lung disease, occurring in 10-15% of patients.'2 Although many patients are symptomless at presentation, aspergillomas have an unpredictable natural history and are a substantial additional burden in terms of morbidity and mortality,3 life threatening haemoptysis and the development of invasive aspergillosis being the most serious complications. At present there is no consensus on the most appropriate treatment and this is reflected in the variety of treatments used. Many of these patients have serious underlying lung disease that precludes surgery and the development of effective oral antifungal treatment would be particularly useful for this group. Itraconazole is an orally active triazole antifungal agent with less toxicity and greater in vitro activity against Aspergillus fumigatus than other available agents.4 These features make it a potentially attractive treatment for pulmonary aspergilloma. We conducted an open study of oral itraconazole in nine patients with aspergilloma to determine the effects oftreatment on symptoms, radiographic appearances, and the antibody response to Aspergillus.
Methods
Symptomatic patients aged over 18 years with radiologically defined aspergilloma and IgG antibodies to A fumigatus were eligible irrespective of the underlying lung disease. Nine patients were entered into the study (table) . Four patients had a history of at least one major haemoptysis and all had chronic cough or intermittent haemoptysis or both.
All patients received oral itraconazole 200 mg capsules daily for six months. Their response was determined each month on the basis of symptoms, clinical signs, and levels of IgG antibody to A fumigatus. Chest radiography and lung function tests were performed every two months, with tomography at entry and at six months. In addition, patients kept a diary for 14 days of each month recording symptoms of cough, wheeze, and haemoptysis on a digital scale. After six months the investigators had the option of continuing itraconazole or of observation for a further six months.
Serum IgG specific for A fumigatus was determined by a rapid enzyme linked immunosorbent assay (ELISA) radiological response in patient 4 was associated with a 50% reduction in specific IgG levels but the antibody level rose and symptoms returned within two months of her stopping itraconazole. One patient (No 8) had a major haemoptysis while having the treatment, which settled without further intervention. In the two patients with a radiological response haemoptysis stopped and in one of them the anaemia and high erythrocyte sedimentation rate were corrected.
Itraconazole was well tolerated. One patient developed unstable angina one month after starting treatment and underwent successful coronary artery bypass grafting. The relevance of the angina is uncertain. There was no change in serum transaminase, bilirubin, or blood count during the six months.
DEATHS
Two patients died during the follow up period after stopping itraconazole. One, aged 55 years and with extensive post-tuberculous upper lobe fibrosis, died from respiratory failure after infection a month after stopping itraconazole; the other, aged 51 years with inactive pulmonary sarcoidosis and a left apical aspergilloma, died after a massive haemoptysis seven months after stopping treatment. Neither had shown any signs of response to itraconazole. 
